TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT01191034

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Cause of deathSlow enrollment Automatic label, confidence 0.5, unverified. How labels are made.
“Completion after 2 patients then stop due to end of validity of vaccine peptide”

The sponsor’s own words in the registry.

Life of this trial

2010201120122013Started2010-08Registered2010-08-27Stopped2012-08-01Primary completion2012-08

Vital statistics

Status
Terminated
Phase
Phase 1, Phase 2
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor type
University, hospital or other
Conditions
Metastatic Melanoma
Interventions
Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
Participants
2
Sites
1
Countries
Belgium

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.